Teachers Retirement System of The State of Kentucky Sells 15,249 Shares of Glaukos Corporation $GKOS

Teachers Retirement System of The State of Kentucky trimmed its stake in Glaukos Corporation (NYSE:GKOS) by 52.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 14,051 shares of the medical instruments supplier’s stock after selling 15,249 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Glaukos were worth $1,586,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Smartleaf Asset Management LLC lifted its stake in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares during the last quarter. CWM LLC raised its holdings in shares of Glaukos by 25.2% in the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares during the period. Evergreen Capital Management LLC raised its holdings in shares of Glaukos by 4.3% in the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 145 shares during the period. UMB Bank n.a. raised its holdings in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 158 shares during the period. Finally, Focus Partners Wealth raised its holdings in shares of Glaukos by 6.9% in the third quarter. Focus Partners Wealth now owns 2,714 shares of the medical instruments supplier’s stock worth $202,000 after buying an additional 176 shares during the period. 99.04% of the stock is owned by institutional investors.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 15,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the transaction, the director directly owned 18,806 shares in the company, valued at $2,207,448.28. This trade represents a 44.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Alex R. Thurman sold 2,511 shares of Glaukos stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the transaction, the chief financial officer owned 41,967 shares in the company, valued at $4,467,806.82. This represents a 5.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 19,657 shares of company stock worth $2,250,060 over the last 90 days. 6.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GKOS. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Stifel Nicolaus increased their price target on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Piper Sandler reiterated an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. BTIG Research reiterated a “buy” rating and issued a $131.00 price target on shares of Glaukos in a report on Wednesday, February 18th. Finally, Needham & Company LLC increased their price target on Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average target price of $133.69.

Glaukos Trading Down 1.9%

GKOS opened at $119.71 on Wednesday. The stock’s fifty day moving average is $113.59 and its two-hundred day moving average is $107.37. The company has a market capitalization of $7.01 billion, a P/E ratio of -36.72 and a beta of 0.78. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $130.23. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $143.12 million for the quarter, compared to analysts’ expectations of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The company’s revenue for the quarter was up 35.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.40) earnings per share. Analysts forecast that Glaukos Corporation will post -0.57 earnings per share for the current year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.